OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gerritsen on Shortcomings of Immunotherapy in Prostate Cancer

October 26th 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses some of the recent shortcomings seen with immunotherapy agents in the treatment of patients with castration-resistant prostate cancer.

Dr. Marcus Bosenberg on Mouse and Other Models for Immunotherapy

October 26th 2016

Marcus Bosenberg, MD, PhD, associate professor of dermatology and pathology, Yale University, discusses mouse models for testing immunotherapies.

Dr. Mesa on NCCN Guidelines for MPNs

October 26th 2016

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).

Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC

October 25th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non–small cell lung cancer (NSCLC).

Dr. George Somlo on Treatment Considerations for Multiple Myeloma

October 25th 2016

George Somlo, MD, medical oncologist, City of Hope, discusses treatment considerations in multiple myeloma.

Dr. Hossein Borghaei on Selecting Checkpoint Inhibitors in NSCLC

October 25th 2016

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab (Keytruda) in second-line non–small cell lung cancer (NSCLC).

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

October 25th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discuses the key takeaways from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Dr. Garon on Concerns for Immunotherapy Combinations in Lung Cancer

October 24th 2016

Edward B. Garon, MD, director, Thoracic Oncology, Jonsson Comprehensive Cancer Center, UCLA, discusses his concerns for potential immunotherapy combinations for the treatment of patients with lung cancer.

Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

October 24th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.

Dr. David Nanus on Atezolizumab for Urothelial Bladder Cancer

October 22nd 2016

David Nanus, MD, medical oncologist, Weill Cornell Medicine, discusses the impact of atezolizumab for patients with advanced urothelial bladder cancer.

Dr. Carey on Possibility of Immunotherapy in HER2+ Breast Cancer

October 22nd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the possibility of administering immunotherapy as treatment for patients with HER2-positive breast cancer.

Dr. Marcom Reflects on Field of HR+ Breast Cancer

October 22nd 2016

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses how the field of hormone receptor (HR)-positive breast cancer has evolved.

Dr. Luke Nordquist on Who Should Receive Radium-223

October 21st 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.

Dr. Luke on Immunotherapy Diagnostics in Melanoma

October 20th 2016

Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC

October 20th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.

Dr. Anders on Challenge of Brain Mets in Breast Cancer

October 20th 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses why brain metastases is such a prominent issue in patients with breast cancer in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.

Dr. Patrick M. Forde on Neoadjuvant Nivolumab in NSCLC

October 20th 2016

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses a study presented at ESMO 2016 on neoadjuvant nivolumab, in early stage resectable non-small-cell lung cancer (NSCLC).

Dr. Fonseca on Pivotal Trials in Multiple Myeloma

October 20th 2016

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discusses some of the ongoing clinical trials that could be potentially practice changing for the treatment of patients with multiple myeloma.

Dr. Reeder on Evolving Role of R-CHOP in Aggressive Lymphomas

October 20th 2016

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas.

Dr. Rosenthal on Treatment Strategies for Indolent Lymphomas

October 20th 2016

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.